Nature Communications (Jun 2022)

A phase 1b randomised controlled trial of a glucagon-like peptide-1 and glucagon receptor dual agonist IBI362 (LY3305677) in Chinese patients with type 2 diabetes

  • Hongwei Jiang,
  • Shuguang Pang,
  • Yawei Zhang,
  • Ting Yu,
  • Meng Liu,
  • Huan Deng,
  • Li Li,
  • Liqi Feng,
  • Baili Song,
  • Han Han-Zhang,
  • Qingyang Ma,
  • Lei Qian,
  • Wenying Yang

DOI
https://doi.org/10.1038/s41467-022-31328-x
Journal volume & issue
Vol. 13, no. 1
pp. 1 – 8

Abstract

Read online

Glucagon-like peptide-1 receptor (GLP1R) agonists are used to treat type 2 diabetes (T2D), and polyagonists targeting multiple hormone receptors are investigated as potential therapeutics for T2D. Here the authors report that IBI362 (LY3305677), a balanced once-weekly GLP-1 and glucagon receptor dual agonist, showed favourable safety and tolerability in Chinese patients with type 2 diabetes in a randomized controlled phase 1b clinical trial.